ArticleMedicine2025
Effects of Huaier extract and autophagy factors on cholangiocarcinoma.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Potential Mechanism of Anti-tumor Effect of Trametes robiniophila Murr. (Huaier).Chinese journal of integrative medicine · 2026Review
- Progress in clinical applications and mechanistic studies of the antitumor effects of Huaier granules.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aims to investigate the mechanisms by which Huaier extract and autophagy-related factors influence biological functions such as survival and proliferation in cholangiocarcinoma cells. HUCCT1 and QBC939 cholangiocarcinoma cell lines were treated with varying concentrations of Huaier extract (0, 20, 40, and 100 mg/mL) for 24 hours. Cell viability and proliferation were assessed using CCK8 and EdU assays. Flow cytometry was employed to analyze cell cycle distribution and apoptosis. Transwell assays evaluated cell migration and invasion capabilities. Western blotting analyzed protein expression levels of P53, phosphorylated P53, AKT, phosphorylated AKT, ribosomal protein S6, Bcl-2, and Bax in control and high-dose Huaier-treated groups. To explore the role of autophagy in cholangiocarcinoma, gene expression datasets were retrieved from the Gene Expression Omnibus for differential expression analysis. Weighted gene co-expression network analysis identified key gene modules. Protein-protein interaction networks and functional enrichment analyses were conducted, with gene expression heatmaps generated. The comparative toxicogenomics database was used to associate core genes with diseases, while TargetScan predicted microRNAs regulating differentially expressed genes. In HUCCT1 cells, Huaier treatment reduced viability and proliferation in a dose-dependent manner and increased apoptosis. High-dose Huaier significantly decreased Bcl-2, RPS6, AKT, and phosphorylated AKT protein levels. Similarly, in QBC939 cells, Huaier reduced viability, proliferation, migration, and invasion, while promoting apoptosis. High-dose treatment notably decreased RPS6 expression and significantly increased P53 and phosphorylated P53 levels. Bioinformatics analysis identified 4248 differentially expressed genes in cholangiocarcinoma samples. Three core autophagy-related genes (BECN1, ATG7, and DRAM1) were pinpointed. These genes were enriched in autophagy processes, cytoplasmic functions, autophagosome membrane formation, the PI3K-Akt signaling pathway, and apoptosis, with elevated expression in tumor samples. Comparative toxicogenomics database analysis linked these core genes to cholangiocarcinoma, inflammation, necrosis, and proliferation. Huaier extract and autophagy factors Beclin 1, autophagy-related gene 7, and damage-regulated autophagy modulator 1 play significant roles in regulating the growth and proliferation of cholangiocarcinoma cells, highlighting potential therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.